Yes, Ranbaxy is an Indian Company. Founded in 1961 and operating until 2014, Ranbaxy Laboratories Limited is a multinational pharmaceutical corporation with its headquarters located in India. The company went public in 1973. Over the course of its existence, Ranbaxy’s ownership has changed three times. After the Japanese pharmaceutical behemoth Daiichi Sankyo acquired the majority of Ranbaxy’s equity in 2008, Sun Pharma bought all of the company’s stock in an all-stock deal in 2014. Sun is currently the world’s fifth-largest generic specialty pharmaceutical company. This manufacturer of pharmaceuticals has a goal of offering high-quality, reasonably priced medications.
| Detail | Info |
| Founded | 1961 |
| Founder | Ranbir Singh and Gurbax Singh |
| Headquarters | Gurgaon, Haryana, India |
| CEO | Former-Arun Sawhney; Acquired by Sun Pharma in 2014 |
| Sector | Pharmaceuticals (Generic Drugs) |
Company History
In 1937, Ranbir Singh and Gurbax Singh founded Ranbaxy, a distributor for the Japanese business Shionogi. The names of its founders, Ranbir and Gurbax, are combined to form Ranbaxy. In 1952, Bhai Mohan Singh bought the company from his cousins Ranbir and Gurbax. The business grew after Parvinder Singh, the son of Bhai Mohan Singh, joined it in 1967.
An important part of its early development was contributed by Bhai Mohan Singh. The US market expansion was spearheaded by Parvinder Singh. The CEO of Ranbaxy Laboratories was Arun Sawhney.
To meet the need for less expensive generic medications in the US, Ranbaxy established Ranbaxy Pharmaceuticals as its American affiliate in the late 1990s. Parvinder collaborated with American entrepreneur Agnes Varis to oversee this growth.
Current Status
Ranbaxy Labs is no longer a stand-alone company. In 2015, Sun Pharmaceutical Industries purchased it. March 25, 2015, marked the completion of the transaction. As a result, Ranbaxy is no longer a distinct, publicly traded firm but rather a division of Sun Pharma. The company produces and distributes antiretrovirals, active pharmaceutical components, intermediates, value-added and over-the-counter drugs, and generic and branded generic medications.
Ranbaxy Laboratories Ltd. has merged with another firm, as evidenced by the fact that it is currently labeled as “Amalgamated” in the company data. The legacy of Ranbaxy has influenced the Indian pharmaceutical industry, and Sun Pharma is currently a top worldwide specialty generic firm.
Future Outlook
Ranbaxy, which operates in 125 countries, is one of the top 10 global generic companies. More than 13,000 skilled workers from more than 50 different countries manage and run it. In addition to having a significant market share in the global market, it is also well-known in India. It has seven manufacturing facilities and operates in about 50 countries. The main internal components of Ranbaxy’s business that provide it a competitive edge and solidify its position are examined in its strengths.